Newsroom News Archive Publications Contact Us for Experts
Media Contacts
Karen Kreeger
PENN Medicine
(215) 349-5658
Rachel Salis-Silverman
Children's Hospital of Philadelphia
(267) 426-6063
Related Links
Perelman School of Medicine
University of Pennsylvania Health System
 
> Epigenetics Shapes Fate of Brain vs. Brawn Castes in Carpenter Ants
> Molecular Master Switch for Pancreatic Cancer Identified, Potential Predictor of Treatment Outcome
> Eat to Dream: Penn Study Shows Dietary Nutrients Associated with Certain Sleep Patterns
  All News Releases
 
    Media Resources
 
spacerNEWS RELEASE spacer Print Version
OCTOBER 3, 2006
  Penn Leads $98 Million Translational Medicine Collaboration
   

(Philadelphia, PA) - The National Institutes of Health (NIH) has awarded the University of Pennsylvania School of Medicine $68 million over the next five years, along with The Children’s Hospital of Philadelphia. Institutional commitments of $30 million bring the Philadelphia consortium’s total to nearly $100 million.

In addition to the Philadelphia collaboration, 11 other academic health centers throughout the nation are receiving these awards. An additional 52 institutions are receiving planning grants to help them prepare applications to join the consortium. When fully implemented in 2012, about 60 institutions will be linked together to energize the discipline of clinical and translational science.

NIH Director Elias A. Zerhouni, MD, today announced the launch of this national consortium that will transform how translational biomedical research is conducted. This new consortium is funded through NIH Clinical and Translational Science Awards (CTSAs). “The development of this consortium represents the first systematic change in our approach to clinical research in 50 years,” says Zerhouni. “Working together, these sites will serve as discovery engines that will improve medical care by applying new scientific advances to real-world practice. We expect to see new approaches reach underserved populations, local community organizations, and health care providers to ensure that medical advances are reaching the people who need them.”

“This award to the School of Medicine and its collaborators will help us use our biomedical research and medical education programs to benefit our patients even more greatly,” says Arthur Rubenstein, MBBCh, Executive Vice President of the University of Pennsylvania for the Health System and Dean, School of Medicine. “It will enhance the development of interdisciplinary structures designed to foster and facilitate research and education in the emerging discipline of translational medicine.”

“The Philadelphia collaboration will act as a vital catalyst for us to undertake a programmatic transformation heralded two years ago by the foundation of the Institute for Translational Medicine and Therapeutics,” says Garret FitzGerald, MD, Director of the Institute and and principal investigator of the CTSA. “Crucially, the award application process has engaged the School of Medicine with The Children’s Hospital of Philadelphia, the Wistar Institute, and the University of the Sciences of Philadelphia, along with eight other schools at Penn to form a truly interdisciplinary alliance to facilitate clinical and translational research. Our major educational investment will support the emergence of a new breed of investigators who will realize the fruits of basic research and deliver them to the community in the years to come.” In addition to educational goals, the Philadelphia translational medicine alliance will develop better designs for clinical trials; design new and improved clinical research informatics tools; expand outreach to minority and medically undeserved communities; and forge new partnerships with private and public health care organizations.

“Children’s Hospital is delighted to be among the first of pediatric hospitals benefiting from CTSAs and we look forward to participating in this interdisciplinary alliance with Penn and the other partners to advance the infrastructure and efficiency of research,” says Peter Adamson, MD, Director, Office of Clinical and Translational Research at Children’s Hospital. “Penn and Children’s Hospital have a long history of collaboration between investigators, but by combining efforts under the CTSA, the depth and breadth of infrastructure support will advance the pace and foster new areas of critical research.”

One example of how the grant will streamline research is by development of a sophisticated approach to improving the effective use of medications for pediatric patients. Computerized programs can combine data from laboratory studies, results and findings from related drugs, and using highly sophisticated mathematical modeling and simulation techniques, help researchers predict the most effective dosages and delivery methods for particular drugs. “We can take a promising new molecule and expedite some of the more laborious, time-consuming traditional methods to provide a systematic approach to estimating drug dosages before we use those doses in patients enrolling on a clinical trial,” says Adamson.

The CTSA grant will enable Children's Hospital to reach a new level of informatics technology with the creation of a “E-Port,” a cross-institutional website that will guide researchers through the regulatory and approval process and create a central location for all documentation, thus making the business of conducting research streamlined and more efficient.

The Institute for Translational Medicine and Therapeutics (ITMAT ) at Penn anticipated many aspects of this new initiative, among them, inclusion of the NIH-funded Penn and Children’s Hospital General Clinical Research Centers, dedicated “dry” and “wet” bench space for translational research, and a robust educational program, based on an MS degree in Translational Research, within the institute.

ITMAT, designated as the “academic home” for clinical and translational research, has been broadened to serve a transinstitutional role. Its structure has been transformed to foster interdisciplinary science from discovery of new molecules through to the study of drug action in large populations. This change has been accomplished by developing interdisciplinary centers, related cores, innovative interdisciplinary programs of research, and strategies to engage and inform communities and their physicians. A particular emphasis has been placed on interdisciplinary training and on broadening the reach of the educational initiatives to span from undergraduate students to mature clinicians and scientists.

###

PENN Medicine is a $2.9 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.

Penn's School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #3 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three hospitals, all of which have received numerous national patient-care honors [Hospital of the University of Pennsylvania; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

 



About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2013, The Trustees of the University of Pennsylvania